Home › Novartis agrees to sell its flu vaccine business to CSL of Australia for $275 million
 

Keywords :   


Novartis agrees to sell its flu vaccine business to CSL of Australia for $275 million

2014-10-27 22:24:44| Biotech - Topix.net

CSL Ltd. said the deal will make it the second-largest flu vaccine maker in the world. The company said the Novartis business had $527 million in revenue in 2013 and said its combined revenue could reach $1 billion a year in three to five years.

Tags: business sell australia million

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Ansell Completes Acquisition of Kimberly-Clarks PPE Business
02.07Ecolab Launches 100% Plastic-Free Wipe for Healthcare Settings
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Chattanooga Area High School Students Graduate from BASFs TECH Academy
02.07Atlantic Tropical Weather Outlook
02.07Fayette Pipe Transforms Black Steel Pipe with FayetteGuard
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Public Advisory Number 16A
More »